Kushenol K

Kushenol K

SCHEMBL27013479

C=C(C)[C@H](CCC(C)(C)O)Cc1c(O)cc(OC)c2c1O[C@H](c1ccc(O)cc1O)[C@H](O)C2=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 9/20 0.72
▸ SLC5A1 P13866 2/20 0.56
▸ SLC5A2 P31639 2/20 0.56
▸ PTGS1 P23219 2/20 0.56
▸ ESR1 P03372 2/20 0.56
▸ SOAT1 P35610 1/20 0.56
▸ BCHE P06276 1/20 0.56
▸ ACHE P22303 1/20 0.56
▸ CACNA1G O43497 1/20 0.46
▸ CACNA1H O95180 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ PDPK1 O15530 1/20 0.37
▸ PRKCA P17252 1/20 0.37
▸ PRKCQ Q04759 1/20 0.37
▸ AKR1B10 O60218 1/20 0.37
▸ AKR1B1 P15121 1/20 0.37
▸ SLCO2B1 O94956 1/20 0.35
▸ SLCO1B3 Q9NPD5 1/20 0.35
▸ SLCO1B1 Q9Y6L6 1/20 0.35
▸ ELANE P08246 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Kushenol K SCHEMBL564142 1.00 BACE1 (0.72) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL564366 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL564568 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL27013512 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL30451391 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol N SCHEMBL27013513 0.87 BACE1 (0.73) BACE1SLC5A1SLC5A2PTGS1ESR1
Kurarinol SCHEMBL27013517 0.84 BACE1 (1.00) BACE1SLC5A1SLC5A2PTGS1ESR1
Kurarinol SCHEMBL29460259 0.84 BACE1 (1.00) BACE1SLC5A1SLC5A2PTGS1ESR1
SCHEMBL29931025 0.81 BACE1 (0.91) BACE1SLC5A1SLC5A2PTGS1ESR1
Kushenol X SCHEMBL4809925 0.77 BACE1 (0.72) BACE1SLC5A1SLC5A2PTGS1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 — — US disclosed
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS THPO, SERPINB1, SERPINC1 BACE1 3298/4885SLC5A1 77/4885SLC5A2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback